Search
Avidity Biosciences Inc
RNAAdd to Watchlist
12.660USD
+0.180+1.44%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
216.56MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Avidity Biosciences Inc is 8.00, ranking 55 out of 157 in the Pharmaceuticals industry. The average price target is 72.00, with a high of 96.00 and a low of 65.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
25.000
Target Price
+97.47%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Avidity Biosciences Inc
RNA
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Avidity Biosciences Inc's expected revenue for the next quarter?
Avidity Biosciences Inc's expected revenue is 1.00M.
What is Avidity Biosciences Inc's price target?
Analysts forecast that Avidity Biosciences Inc's price target is USD 72.00, with the highest forecast at USD 96.00 and the lowest forecast at USD 65.00.
How have Avidity Biosciences IncRNA's recent earnings per share performed?
The market expectation was USD -0.97, while Avidity Biosciences IncRNA's earnings per share (EPS) for the previous quarter was USD -1.70. EPS for the next quarter is expected at USD -1.16.
What is the analyst rating for Avidity Biosciences Inc?
Based on the ratings of Avidity Biosciences Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
